Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA

PBI-200 is being developed for the treatment of NRTK fusion-positive solid tumors, including primary and metastatic brain tumorsPBI-200 is presently being evaluated in a global Phase 1/2 multicenter clinical trialWALTHAM, Mass.--(BUSINESS WIRE)--#NRTK--Pyramid Biosciences, Inc., a clinical-stage biotechnology compan...

Related Keywords

United States ,Jordan ,Brian Lestini ,Biosciences Inc ,Office Of Orphan Drug Products ,Mcdougall Communications ,Drug Administration ,Pyramid Biosciences ,Orphan Drug Products ,Biosciences Media Inquiries ,Dougall Communications ,